| Name | aspartate aminotransferase |
|---|---|
| Synonyms | Aspartate Aminotransferase 1; GIG18; GOT 1; GOT1; Aspartate aminotransferase; Glutamate oxaloacetate transaminase 1; Transaminase A; Aspartate aminotransferases… |
| Name | oxamate |
|---|---|
| CAS | hexyl 2-(diethylamino)-2-oxoacetate |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 7379304 | Lustig V, Redman LW: Improved serum-initiated aspartate aminotransferase assay by inhibition of lactate dehydrogenase with oxamate. Clin Chem. 1980 Jun;26(7):831-4. |
82(1,1,1,2) | Details |
| 535158 | Lustig V, Redman LW: Improved serum initiated aspartate aminotransferase assay by inhibition of lactate dehydrogenase with oxamate. Clin Biochem. 1979 Dec;12(6):254-5. |
81(1,1,1,1) | Details |
| 466765 | Rej R: Measurement of aspartate aminotransferase activity: effects of oxamate. . Clin Chem. 1979 Apr;25(4):555-9. Oxamate, a potent inhibitor of lactate dehydrogenase, is shown also to inhibit aspartate aminotransferase activity, both in human serum and in purified isoenzymes of human origin. |
68(0,2,3,3) | Details |
| 18922152 | Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J: Targeting aspartate aminotransferase in breast cancer. . Breast Cancer Res. 2008;10(5):R84. Epub 2008 Oct 15. Oxamate is an inhibitor of both LDH and AAT, and we hypothesised that oxamate may disrupt the metabolism and growth of breast adenocarcinoma cells. |
2(0,0,0,2) | Details |
| 12075544 | Collins ND, LeRoy BE, Vap L: Artifactually increased serum values in two horses and a calf with severe rhabdomyolysis. Vet Clin Pathol. 1998;27(3):85-90. All three animals had severe muscle disease as evidenced by markedly increased aspartate aminotransferase and kinase activities. It was hypothesized that increased serum lactate dehydrogenase (LDH) activity and concentration overwhelmed the oxamate LDH inhibitor in the enzymatic HCO3- assay, resulting in consumption of and falsely elevated spectrophotometric reading. |
1(0,0,0,1) | Details |